Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kenvue

Johnson & Johnson investors who elected to participate in the swap will see just 23.8% of their shares converted into Kenvue stock

J&J Exchange Offer for Kenvue Is Substantially Oversubscribed

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that, based on preliminary results, its previously announced offer to its shareholders to exchange their shares of Johnson & Johnson common stock for shares of Kenvue Inc. (NYSE: KVUE) (“Kenvue”) common stock owned by Johnson & Johnson was oversubscribed. The exchange offer expired at 12:00 midnight, New York City time, at the end of the day on August 18, 2023. Under the terms of the exchange offer,.

Johnson & Johnson Announces Preliminary Results of Kenvue Inc. Exchange Offer

Caterpillar

Dover

Coca-Cola

Microsoft

PepsiCo

Procter & Gamble

Generating passive income is easier said than done. A lot of investors look for dividend stocks to enjoy steady and consistent income.

The 7 Most Undervalued Dividend Stocks to Buy Now: August 2023

Amazon

3 Stocks I Will "Never" Sell

Automatic Data Processing

Costco

Cisco Systems

Hershey

NIKE

SPDR S&P 500 ETF Trust

Visa

Walmart

The article presents the ten highest-quality Dividend Radar stocks for further research and possible investment. To rank stocks, I do a quality assessment and sort stocks by quality scores, breaking ties with additional metrics. Different stocks are recommended for different investment styles, including income investors, value investors, and growth-oriented investors.

10 Dividend Growth Stocks For August 2023

J&J's (JNJ) Pharma sales are being driven by key drugs like Darzalex and new products. J&J's Pharma and MedTech units are likely to continue to drive sales growth in 2023.

Here's Why it is a Good Time to Buy J&J's (JNJ) Stock Now

Kenvue Inc. is the largest OTC drug company on earth, with the most trusted brands and impressive free cash flow margins that are expected to keep improving over time. It's likely to become a dividend king next year when Kenvue confirms it will keep raising the dividend each year. Kenvue is an A-rated company whose leverage ratio is expected to decline and potentially achieve an A+ rating by 2027.

Johnson & Johnson Vs. Kenvue: The Better Dividend Aristocrat Might Shock You

Mastercard

PennantPark Floating Rate Capital

Headline-inflation data suggests the Fed's monetary policy is finding its mark. However, the most important component of core inflation has put the nation's central bank in a seemingly no-win situation.

Opinion: The Fed Is Losing the Battle Against Inflation, and There's No Easy Fix

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced the final exchange ratio for its previously announced split-off exchange offer to Johnson & Johnson shareholders to exchange their shares of Johnson & Johnson for shares of common stock of Kenvue Inc. (NYSE: KVUE) (“Kenvue”) currently held by Johnson & Johnson. For each share of Johnson & Johnson common stock that is validly tendered and not validly withdrawn by shareholders and that is accep.

Johnson & Johnson Announces Final Exchange Ratio of 8.0324 in Split-Off of Kenvue Inc.

The past few years have made many people realize the importance of building a retirement portfolio. Having dealt with a pandemic, layoffs, and inflation, investors realize the importance of having a solid portfolio that sustains any market situation.

The 3 Most Undervalued Retirement Stocks to Buy Now: August 2023

Johnson & Johnson (NYSE:JNJ ) UBS MedTech, Tools and Genomics Summit Conference Call August 15, 2023 2:00 PM ET Company Participants Celine Martin - Group Chairman Jasmina Brooks – President, Biosense Webster Anthony Hong - Vice President, Preclinical and Clinical Research and Medical Affairs Conference Call Participants Danielle Antalffy - UBS Danielle Antalffy Alright. Good morning, everyone.

Johnson & Johnson (JNJ) Presents at UBS MedTech, Tools and Genomics Summit Conference (Transcript)

Renewed uncertainty in relation to Johnson & Johnson's talc lawsuit settlement led to a brief and temporary selloff in JNJ stock. What was Mr. Market thinking? It looks like a "once and for all" resolution regarding J&J's talc lawsuits is now off the table, and the company could face time-consuming litigation on a case-by-case basis. I share my outlook on Johnson & Johnson's talc lawsuits, and the potential consequences of Judge Kaplan's recent ruling.

Johnson & Johnson Stock: Outlook Amid Lawsuits

AbbVie

Home Depot

Kroger

Philip Morris

Sempra Energy

While optimism in the broader market remains robust – particularly for hyped-up sectors like technology – investors may still want to consider the relative safety of dividend stocks to buy. Notably, in the trailing month, the benchmark S&P 500 index went absolutely nowhere.

7 Dividend Stocks to Buy as Investor Sentiment Falters

The $40 billion exchange offer for shares of Kenvue expires Friday but brokerage firms want retail investors to make their instructions before then

J&J Investors Need to Decide Soon If They Want Kenvue Stock

Two weeks ago, Fitch downgraded the U.S. credit rating from AAA to AA+. This matched the downgrade issued by Standard & Poor's (S&P) in 2011.

Meet the Only 2 Publicly Traded Companies With a Higher Credit Rating Than the U.S. Government

Equinix

T-Mobile US

In the ever-fluctuating stock market landscape, navigating bear markets can be a nerve-wracking experience for even the most seasoned investors. When stock prices plunge and economic clouds gather, it's natural to question whether investing during such turbulent times is wise.

5 Best Stocks to Buy in a Bear Market

Bristol-Myers

First Trust Nasdaq Pharmaceuticals ETF 

iShares U.S. Pharmaceuticals ETF

Eli Lilly

Merck

Pfizer

Invesco Dynamic Pharmaceuticals ETF

VanEck Vectors Pharmaceutical ETF

SPDR S&P Pharmaceuticals ETF

Second-quarter earnings beat ratio of 86.6% and revenue beat ratio of 84.9% for the healthcare sector are impressive.

Pharma ETFs in Focus Post Q2 Earnings

Amgen

It's still unclear which drugs Medicare will select, but several companies have revealed in court filings that four of their medications are targets.

These 10 medications are likely targets for Medicare price negotiations this fall

Kenvue is set to make its debut in the S&P 500 index, a move confirmed by S&P Dow Jones Indices following the impending completion of Johnson and Johnson's exchange offer for Kenvue stock. The inclusion comes after Kenvue's nearly $47 billion initial public offering by Johnson and Johnson in May.

J&J spinoff Kenvue set to join S&P 500 index

Johnson & Johnson said on Thursday the U.S. Food and Drug Administration had approved its antibody-based therapy for patients with a difficult-to-treat type of blood cancer.

US FDA approves J&J's blood cancer therapy

Dollar General

Flowers Foods

As the Nasdaq starts to plateau and more economists signal volatility ahead, it might once again be time to look for a port in the storm. Last year, investors that bought into the safest stocks had solid insulation from the widespread market selloff.

News for Johnson & Johnson Stock (JNJ)